Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 74,500 shares, a decline of 44.7% from the September 30th total of 134,800 shares. Currently, 1.2% of the shares of the company are short sold. Based on an average trading volume of 163,600 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 163,600 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.2% of the shares of the company are short sold.

Institutional Trading of Traws Pharma

An institutional investor recently bought a new position in Traws Pharma stock. Adage Capital Partners GP L.L.C. acquired a new position in Traws Pharma, Inc. (NASDAQ:TRAW) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 330,000 shares of the company’s stock, valued at approximately $759,000. Adage Capital Partners GP L.L.C. owned 6.19% of Traws Pharma at the end of the most recent quarter. 7.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Traws Pharma in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Traws Pharma Stock Performance

Shares of TRAW opened at $2.64 on Friday. Traws Pharma has a fifty-two week low of $0.97 and a fifty-two week high of $19.44. The business has a 50-day moving average of $2.14 and a 200 day moving average of $1.74. The firm has a market cap of $18.82 million, a P/E ratio of 0.03 and a beta of 1.69.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($8.75) by $8.64. The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $0.06 million. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 1,812.48%.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.